SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$246M
Q4 2022
Positions
55
Filings on Record
24
2019–present window
Filed
Feb 14, 2023
original filing

Summary

Endurant Capital Management LP reported $246M in U.S.-listed holdings across 55 positions for Q4 2022.

Its largest position, Invacare, represents 19.8% of the portfolio.

Compared with Q3 2022, the fund opened 29 new positions and exited 23.

Portfolio Metrics

Turnover
+32.0%
vs prior filed quarter
Top-10 Concentration
+67.4%
share of reported value
Largest Position
+19.8%
Invacare
New / Exited
29 / 23
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 52.5%US DOMESTIC: 19.8%Other: 15.2%ADR: 6.2%PRIV PLACEMENT: 3.4%Other: 2.8%
  • Common Stock · 52.5% · $129M
  • US DOMESTIC · 19.8% · $49M
  • Other · 15.2% · $37M
  • ADR · 6.2% · $15M
  • PRIV PLACEMENT · 3.4% · $8M
  • Other · 2.8% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MRKMERCK & CO INCNEW+126.0K126.0K+$14M$14M
CNCCENTENE CORP DELNEW+168.4K168.4K+$14M$14M
SBCSABRA HEALTH CARE REIT INCNEW+436.5K436.5K+$5M$5M
VKTXVIKING THERAPEUTICS INCNEW+433.0K433.0K+$4M$4M
ABGAMERISOURCEBERGEN CORPNEW+21.0K21.0K+$3M$3M
BNTXBIONTECH SENEW+21.7K21.7K+$3M$3M
SILKUSDSILK RD MED INCNEW+30.0K30.0K+$2M$2M
HCAHCA HEALTHCARE INCNEW+6.6K6.6K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVACARE CORPNOTE 5.000%11/123.21%$57M66.82M
2LABORATORY CORP AMER HLDGSCOM NEW8.69%$21M90.9K
3CICIGNA CORP NEWhistory →COM6.68%$16M49.7K
4MRKMERCK & CO INChistory →COM5.68%$14M126.0K
5CNCCENTENE CORP DELhistory →COM5.61%$14M168.4K
6ELVELEVANCE HEALTH INChistory →COM5.43%$13M26.1K
7ICON PLCSHS4.65%$11M58.9K
8AZNNASTRAZENECA PLChistory →SPONSORED ADR3.89%$10M141.4K
9BMRNBIOMARIN PHARMACEUTICAL INChistory →COM3.55%$9M84.4K
10SBCSABRA HEALTH CARE REIT INChistory →COM2.20%$5M436.5K
11ELUTAZIYO BIOLOGICS INChistory →CL A COM2.17%$5M1.26M
12IM8NINSMED INChistory →COM PAR $.011.97%$5M243.1K
13BDQMALBIREO PHARMA INChistory →COM1.91%$5M217.2K
14EHCENCOMPASS HEALTH CORPhistory →COM1.90%$5M78.1K
15SELECTA BIOSCIENCES INCCOM1.73%$4M3.78M
16VKTXVIKING THERAPEUTICS INChistory →COM1.65%$4M433.0K
17ABGAMERISOURCEBERGEN CORPhistory →COM1.42%$3M21.0K
18BNTXBIONTECH SEhistory →SPONSORED ADS1.32%$3M21.7K
19OCULOCULAR THERAPEUTIX INChistory →COM1.21%$3M1.06M
20ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.03%$3M1.73M
21ZTSZOETIS INCCL A1.00%$2M16.7K
22SUTRO BIOPHARMA INCCOM0.92%$2M281.9K
23QIAGEN NVSHS NEW0.83%$2M40.7K
24THCTENET HEALTHCARE CORPCOM NEW0.80%$2M40.5K
25BDXBECTON DICKINSON & COCOM0.70%$2M6.8K
26BUWABIO RAD LABS INCCL A0.66%$2M3.9K
27CTLTEURCATALENT INCCOM0.64%$2M35.3K
28SILKUSDSILK RD MED INCCOM0.64%$2M30.0K
29HCAHCA HEALTHCARE INCCOM0.64%$2M6.6K
30DOCHEALTHPEAK PROPERTIES INCCOM0.61%$1M59.6K
31430TERNS PHARMACEUTICALS INCCOM0.56%$1M136.0K
32CHARLES RIV LABS INTL INCCOM0.55%$1M6.3K
33ARWRARROWHEAD PHARMACEUTICALS INCOM0.46%$1M28.2K
34BCABGBPBIOATLA INCCOM0.46%$1M136.4K
35TXG10X GENOMICS INCCL A COM0.45%$1M30.4K
36ALNYALNYLAM PHARMACEUTICALS INCCOM0.44%$1M4.6K
372JQGRITSTONE BIO INCCOM0.40%$976,126282.9K
38TMOTHERMO FISHER SCIENTIFIC INCCOM0.36%$875,0461.6K
39AXSMAXSOME THERAPEUTICS INCCOM0.35%$868,79211.3K
40XRAYDENTSPLY SIRONA INCCOM0.29%$703,28222.1K
41PTCTPTC THERAPEUTICS INCCOM0.28%$682,70917.9K
42NTLAINTELLIA THERAPEUTICS INCCOM0.23%$572,23116.4K
43BAXBAXTER INTL INCCOM0.23%$561,07811.0K
441K0IGM BIOSCIENCES INCCOM0.21%$515,74330.3K
45ATNMACTINIUM PHARMACEUTICALS INCCOM0.20%$485,76845.6K
46ETNBGBP89BIO INCCOM0.19%$468,26036.8K
47IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.18%$451,48570.7K
482662247DITEOS THERAPEUTICS INCCOM0.17%$410,93121.0K
49INBXUSDINHIBRX INCCOM0.13%$332,27013.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.